Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Vaccine

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook

Merck & Co Inc's (NYSE:MRK) Q1 sales reached $15.90 billion, +50% Y/Y, beating the consensus of $14.68 billion. Excluding the foreign exchange impact, revenues were up 52%. Pharmaceutical sales increased 53% to $14.11 billion, primarily driven by molnupiravir, oncology, vaccines, and hospital acute care products. Pharmaceutical sales growth, excluding Lagevrio sales, was…

Benzinga

Sage Steele sues ESPN after remarks on vaccine mandate and Obama’s race

ESPN anchor Sage Steele is suing the network after claiming it curtailed her right to free speech over remarks she made last year

The Guardian - US

Moderna seeks to be 1st with COVID shots for littlest kids

Moderna is asking U.S. regulators to open its COVID-19 vaccine to the nation's youngest children

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna seeks emergency authorization for COVID-19 vaccine in young children

Moderna said last month its vaccine for kids generated a strong immune response.

Axios

Barroso to Asharq Al-Awsat: Saudi Arabia’s Response to the Pandemic a Lesson for Health Systems

Jose Barroso, the chairman of the Global Vaccine Alliance (GAVI), described Saudi Arabia’s response to the Covid-19 pandemic as “wonderful”, pointing that the Kingdom’s investment in health care systems has prepared it to deal better with the pandemic. In an exclusive interview with Asharq Al-Awsat, Barroso, who is also the…

Asharq Al-Awsat

Moderna asks FDA to authorize COVID-19 vaccine for kids under 6 - Roll Call

Moderna said Thursday that it asked the FDA for emergency use authorization of its COVID-19 vaccine in kids under age 6.

Roll Call

A ‘Significant Flu Epidemic’ Is Coming After Cases Tripled This Month & My Sinuses Are Quivering

We went two whole years with cold and flu practically wiped out in Australia thanks to lockdowns and other health measures, but now that everyone’s making out with each other again influenza rates are skyrocketing. Flu cases in NSW more than tripled between March and April and rose way above…

Pedestrian.tv

Read news from The Economist, FT, and more,
with one subscription

Thailand Pass to end on June 1

The cancellation of Thailand Pass registration is expected to take place on June 1, with tourists using their TM6 immigration form for vaccine declaration, says the Tourism and Sports Ministry.

Bangkok Post

4 Biotech Stocks to Add to Your Watchlist

The surging demand for viable drugs and vaccines, advanced therapies, and increasing investments in research and development make the biotech industry’s prospects bright. Thus, it could be wise to invest in fundamentally sound biotech stocks Amgen (AMGN), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Corcept Therapeutics (CORT).

StockNews.com

A timeline of Fauci's predictions about the COVID pandemic

The U.S. is out of a "full-blown explosive pandemic phase" Fauci said this week.

Axios

Victoria stands down 420 public school teachers over vaccine mandates

About half had failed to get a booster shot before the March deadline and have been placed on unauthorised leave

The Guardian - AU

Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age. The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose…

Benzinga

Pig producers say pork safe to eat amid Japanese encephalitis virus vaccine rollout success

Pork producers guarantee consumers it is safe to eat pork, as the country continues to manage Japanese encephalitis virus (JEV).

ABC News

Anticipating a side effect makes it more likely you'll experience it – this could contribute to vaccine hesitancy

The COVID pandemic has highlighted several interesting features of modern medical practice – most recently the “nocebo” response, which may account for a significant number of side effects people experience following vaccination.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

USAFacts

Immunization requirements are common in US schools but few states have added COVID-19 vaccine mandates

States control vaccine mandates for school students. Some vaccines are required nationwide.

Salon

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Tribune News Service

Pfizer asks FDA to clear COVID booster shot for kids 5-11

Pfizer Inc. asked U.S. regulators for emergency-use authorization of a booster shot of its COVID-19 vaccine in children ages 5 to 11, setting in motion an effort to provide extra protection to kids.

The Hindu

COVID-19 vaccination: Nearly 3 lakh citizens yet to take second dose

Health staff tasked with contacting and convincing them to take vaccine

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

COVID-19: Survey shows 30% of respondents who had taken third dose vaccine contracted disease during third wave in India

Questionnaire-based survey conducted by a group of Kochi-based doctors among 5,971 adults across the country to assess the community level experience of the pandemic

Benzinga

GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ:GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle. They are designed to induce an immune response with durable…

Benzinga

Valneva - Pfizer Post Encouraging Data From Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN) and Pfizer Inc (NYSE:PFE) have reported Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. In pediatric participants (5-17 years old) who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested. These…

The Conversation

How Robert Langer, a pioneer in delivering mRNA into the body, failed repeatedly but kept going: 'They said I should give up, but I don't like to give up'

The mRNA vaccines developed against COVID-19 owe a lot to the work of Robert Langer, a pioneer in the delivery of mRNA. Langer, who is the Massachusetts Institute of Technology David H. Koch Institute Professor and director of the Langer Lab, helped lay the foundation for the underlying delivery mechanism…

Sports Illustrated

The Nets’ Season Was Doomed From the Start

Brooklyn had to weather injuries, James Harden’s trade request and other setbacks. But Kyrie Irving’s decision to not get the vaccine stumbled the team out of the gate.

Birmingham Post

Biotech firm ReViral acquired by Pfizer in £412m deal

ReViral was co-founded by former Durham University lecturer Professor Stuart Cockerill and has a North East research and development facility at Sedgfield's NETPark

Evening Standard

David Harewood takes on new role as a vaccine champion in Bangladesh

Returning from a trip to the Bangladeshi highlands, the British actor and Unicef goodwill ambassador is calling on the UK government to do more to protect the world’s poorest against future crises

1 … 272 273 274 275

People

Phiphat Ratchakitprakarn

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

336 stories

Pfizer Inc

313 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.